Cargando…
Dendritic cell immunotherapy: clinical outcomes
The use of tumour-associated antigens for cancer immunotherapy studies is exacerbated by tolerance to these self-antigens. Tolerance may be broken by using ex vivo monocyte-derived dendritic cells (DCs) pulsed with self-antigens. Targeting tumour-associated antigens directly to DCs in vivo is an alt...
Autores principales: | Apostolopoulos, Vasso, Pietersz, Geoffrey A, Tsibanis, Anastasios, Tsikkinis, Annivas, Stojanovska, Lily, McKenzie, Ian FC, Vassilaros, Stamatis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232065/ https://www.ncbi.nlm.nih.gov/pubmed/25505969 http://dx.doi.org/10.1038/cti.2014.14 |
Ejemplares similares
-
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
por: Apostolopoulos, Vasso, et al.
Publicado: (2006) -
Targeting Antigens to Dendritic Cell Receptors for Vaccine Development
por: Apostolopoulos, Vasso, et al.
Publicado: (2013) -
Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR Stimulation
por: Sheng, Kuo-Ching, et al.
Publicado: (2013) -
Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients
por: Kuol, Nyanbol, et al.
Publicado: (2022) -
Role of the nervous system in cancer metastasis
por: Kuol, Nyanbol, et al.
Publicado: (2018)